Drug Profile
NKTR 223
Alternative Names: NKTR-223Latest Information Update: 28 Dec 2017
Price :
$50
*
At a glance
- Originator Nektar Therapeutics
- Class Peptides; Polymers
- Mechanism of Action Cell membrane permeability modulators; Cell membrane structure modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Gram-negative infections
Most Recent Events
- 28 Dec 2017 No recent reports of development identified for preclinical development in Gram-negative-infections in USA (Parenteral)
- 19 Nov 2013 Preclinical trials in Gram-negative infections in USA (Parenteral)